1. Adelaide Research & Scholarship

Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-10 of 13 (Search time: 0.003 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2007Imatinib increases the intracellular concentration of nilotinib which may explain the observed synergy between these drugsWhite, D.; Saunders, V.; Quinn, S.; Manley, P.; Hughes, T.
2013Dasatinib targets chronic myeloid leukemia-CD34⁺ progenitors as effectively as it targets mature cellsHiwase, D.; Saunders, V.; Nievergall, E.; Ross, D.; White, D.; Hughes, T.
2007Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemiaWhite, D.; Saunders, V.; Grigg, A.; Arthur, C.; Filshie, R.; Leahy, M.; Lynch, K.; To, L.; Hughes, T.
2013Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cellsWhite, D.; Eadie, L.; Saunders, V.; Hiwase, D.; Hughes, T.
2007Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activityWhite, D.; Saunders, V.; Dang, P.; Engler, J.; Venables, A.; Zrim, S.; Zannettino, A.; Lynch, K.; Manley, P.; Hughes, T.
2010Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapyHiwase, D.; White, D.; Zrim, S.; Saunders, V.; Vaz de Melo, J.; Hughes, T.
2010The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34⁺ cellsEngler, J.; Frede, A.; Saunders, V.; Zannettino, A.; White, D.; Hughes, T.
2008Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implicationsHiwase, D.; Saunders, V.; Hewett, D.; Frede, A.; Zrim, S.; Dang, P.; Eadie, L.; To, L.; Vaz de Melo, J.; Kumar, S.; Hughes, T.; White, D.
2005In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de-novo CML.White, D.; Saunders, V.; Lyons, A.; Branford, S.; Grigg, A.; To, L.; Hughes, T.
2006OCT-1-mediated influx is a key determinant of the intraceflular uptake of imatinib but not nilotinib, (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinibWhite, D.; Saunders, V.; Dang, P.; Engler, J.; Zannettino, A.; Cambareri, A.; Quinn, S.; Manley, P.; Hughes, T.

Discover